The Clinical Trials noted below are by no means all the available trials. You should speak with your gynecologic oncologist regarding any additional trials of which he/she may be aware.
We are not affiliated with these sites and organizations and cannot confirm the accuracy of any information contained on these sites. Any information obtained should be confirmed with your own physician. No endorsement of these organizations or their sites is made or implied.
RESOURCES FOR CLINICAL TRIALS
HOW TO LEARN ABOUT CLINICAL TRIALS
If you would like to learn more about clinical trials in general, you may want to order the National Cancer Institute's
Taking Part In Clinical Trials: What Cancer Patients Need To Know. Order by calling
800-422-6237 or go to www.cancer.gov/clinicaltrials.
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER CLINICAL TRIALS
The information on the trials noted below was provided by Shelley Sheridan, Research Study Coordinator at
UT Southwestern and an ovarian cancer survivor. We greatly appreciate her assistance in providing this information.
If you are interested in learning more about these trials, please call 214-648-3026 at the UT Southwestern Medical School or email Shelley
at Shelley.Sheridan@UTSouthwestern.edu.
University of Texas Southwestern Medical Center
Division of Gynecologic Oncology
5323 Harry Hines Blvd., J7.124
Dallas, TX 75390-9032
Ph: 214-648-3026
Fax: 214-648-8404
Clinical Trials
Updated: December 2007
Ovarian cancer
Title: Sanofi Study (Phase II study)
Eligibility: Patients with newly diagnosed ovarian cancer.
Sponsor: Sanofi
Trial: Women are treated with the combination of Oxaliplatin, Docetaxel, and Bevacizumab
Contact: Janis Brendle at 214-648-1854
Title: OCEANS (Phase II study)
Eligibility: Patients that have disease recurrence greater than 6 months after platinum based therapy and no prior treatments in the recurrent setting.
Sponsor: Genetech
Trial: Women are treated with Carboplatin and Gemcitabine plus Bevacizumab or placebo.
Contact: Shelley Sheridan at 214-648-7094
Title: OVATURE (Phase II Study)
Eligibility: Patients that have undergone at least two courses of platinum drug therapy and responded to the first course, but ahve since shown disease relapse within 6 months of completion of the second or greater course of platinum therapy
Sponsor: Marshall Edwards
Trial: Women are treated with weekly Carboplatin plus Phenoxodiol or placebo.
Contact: Shelly Sheridan at 214-648-7094
Title: GOG #212 (Phase III study)
Eligibility: Patients who achieve clinical remission with initial chemotherapy and are candidates for additional treatment to reduce the likelihood of relapse
Sponsor: Gynecologic Oncology Group
Trial: Women are treated with Xyotax, Taxol, or no further treatment for 12 months
Contact: Paula HOnea at 214-648-6753
Title: GOG #146-O (Phase II Study)
Eligibility: Patients with recurrent platinum-sensitive ovarian or peritoneal cancer
Sponsor: Gynecologic Oncology Group
Trial: Women are treated with the investigational agent Irofulven
Contact: Paula Honea at 214-648-6753
Cervical Cancer
Title: GOG 219 (Phase III study)
Eligibility: Patients with newly diagnosed cervical cancer limited to the pelvis
Sponsor: Gynecologic Oncology Group
Trial: Women are treated with cisplatin and radiation or cisplatin, tirapazamine and radiation
Contact: Paula Honea at 214-648-6753
Title: VEG105281 (Phase II study)
Eligibility: Patients with stage IVB or recurrent cervical cancer with zero or one prior chemotherapy regimen
Sponsor: GlaxoSmithKline
Trial: Women are treated with pazopanib monotherapy, or lapatinib monotherapy, or combination lapatinib and pazopanib.
Contact: Shelley Sheridan at 214-648-7094
Endometrial Cancer
Title: GOG #209 (Phase III study)
Eligibility: Patients with advanced (stage III-IV) uterine/endometrial cancer
Sponsor: Gynecologic Oncology Group
Trial: Women are randomized to either Taxol/carboplatin or Taxol/Adriamycin/Cisplatin chemotherapy
Contact: Paula Honea at 214-648-6753
Title: GOG #210 (prospective cohort study)
Eligibility: Patients diagnosed with uterine/endometrial cancer by biopsy
Sponsor: Gynecologic Oncology Group
Trial: Blood samples, tumor tissue samples and questionnaires are retried so that molecular studies targeting this cancer can be performed in the future.
Contact: Juanita at 214-648-4916
Title: GOG #188 (Phase II study)
Eligibility: Patients with estrogen receptor negative recurrent or metastatic endometrial cancer
Sponsor: Gynecologic Oncology Group
Trial: Women are treated with the investigational agent Faslodex
Contact: Paula Honea at 214-648-6753
Vulvar Cancer
Title: GOG #173 (prospective cohort study)
Eligibility: Patients with newly diagnosed vulvar cancer
Sponsor: Gynecologic Oncology Group
Trial: This study tests the effectiveness of sentinel lymph node identification
Contact: Paula Honea at 214-648-6753
Title: GOG #205 (Phase II study)
Eligibility: Patients with newly diagnosed advanced vulvar cancer
Sponsor: Gynecologic Oncology Group
Trial: Women are treated with radiation plus weekly cisplatin chemotherapy
Contact: Paula Honea at 214-648-6753
Uterine Sarcoma
Title: GOG #230B (Phase II study)
Eligibility: Patients with recurrent or persistent uterine sarcoma
Sponsor: Gynecologic Oncology Group
Trial: Women are treated with investigational agent Thalidomide
Contact: Paula Honea at 214-648-6753
Title: GOG #232B (Phase II study)
Eligibility: Patients with advanced, persistent, or recurrent uterine carcinosarcoma
Sponsor: Gynecologic Oncology Group
Trial: Women are treated with Carboplatin and Paclitaxel
Contact: Paula Honea at 214-648-6753
| Faculty |
| David S. Miller, MD, FACOG, FACS |
| John O. Schorge, MD, FACOG, FACS |
| Jayanthi W. Lea, MD |
OVATURE CLINICAL TRIAL
OVATURE is a Phase III clinical trial, named for OVArian TUmor REsponse and is for women with recurrent ovarian cancer.
The trial seeks to recruit 235 women in the US and 470 women globally. All patients on the trial will receive carboplatin
weekly, in doses lower than that given when carboplatin is administered in the more typical once every three or four week dosing
regimen. In addition to learning more about the efficacy of phenoxodiol, researchers will learn more about the efficacy of
weekly carboplatin.
- Study Sponsor: Marshall Edwards Inc
Principal Investigator: John Schorge, M.D.
Contact person: Jonathan Thompson at jthompson@sciwords.com
OTHER CLINICAL TRIALS
The information on the trials noted below were provided through various survivors. The requirements, dates, etc
are unconfirmed. Therefore, these are only possible trials to discuss with your physician(s).
- Study Number 04-C-0246
Principal Investigator: James Gulley, M.D.
Called an "open label pilot study" to evaluate the Safety and Tolerability of PanVC V and PanVac F in Patients with Metastatic Carcinoma. Per our patient
source, the study is closed as of January, 2006, but opens again soon for 12 additional women with ovarian cancer.
Contact person: Mary Pazdur, RN 301-496-7870
- In the Winter 2005 issue of Cure Magazine one of our survivors saw an announcement about a Phase II Clinical Trial looking for
women to participate who have platinum-resistant ovarian cancer. It is a randomized, placebo-controlled, Phase II study. There will be
two groups, one taking the placebo and standard chemotherapy whiel the other takes a new drug along with the standard chemotherapy. In many such studies, if you
are in the placebo group and your cancer continues to progress, they may offer the option to move you over to the study drug group. You would
need to discuss this with the clinical trial coordinator.
Contact information: 1-888-662-6728 or go to www.clinicaltrials.gov and search
under identifier NCT00096993.